Transcutaneous Electrical Nerve Stimulation (TENS) for Advanced Cancer Pain Patients

NACompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

March 31, 2018

Study Completion Date

March 31, 2018

Conditions
Advanced Cancer
Interventions
DEVICE

Modulated TENS

"* Frequency: 100 Hz~* Intensity: individual; TENS should be clearly perceptible but not painful; impulse width is coupled with intensity~* Mode: intensity modulation (40% decrease every 0.5 seconds)~* TENS device: ARTROSTIM® SELECT~* Channels: 2~* Electrodes: 4 (5x5cm), placed on site of pain (a little more proximal if allodynia is present)"

DEVICE

Placebo TENS

"* Frequency: 100 Hz (conventional for High TENS; Placebo is achieved by reduction of intensity, see below)~* Intensity: The device is on and will be up-regulated together until the first sensation is perceptible. Then the activated device will be down-regulated minimally (no sensation perceptible) and this configuration will be retained.~* Mode: continuous~* TENS device: ARTROSTIM® SELECT~* Channels: 2~* Electrodes: 4 (5x5cm), placed on site of pain (a little proximal if allodynia is present)"

Trial Locations (1)

Unknown

Clinic for Palliative Care, Medical Center, University of Freiburg, Freiburg im Breisgau

All Listed Sponsors
lead

University Hospital Freiburg

OTHER

NCT02655289 - Transcutaneous Electrical Nerve Stimulation (TENS) for Advanced Cancer Pain Patients | Biotech Hunter | Biotech Hunter